NASDAQ:ITCI
Intra-Cellular Therapies Inc. Stock News
$65.00
-1.53 (-2.30%)
At Close: May 17, 2024
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
01:45pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
12:30pm, Wednesday, 01'st Mar 2023 GlobeNewswire Inc.
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Wednesday, 01'st Mar 2023
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
03:00pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know
03:00pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates
10:25pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
01:00pm, Tuesday, 14'th Feb 2023 GlobeNewswire Inc.
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central n
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
08:00am, Tuesday, 14'th Feb 2023
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
01:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
08:00am, Wednesday, 08'th Feb 2023
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
01:00pm, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 03'rd Jan 2023
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
03:53pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
02:40pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
11:18am, Thursday, 22'nd Dec 2022
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
